[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-tumor-unspecified-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-tumor-unspecified-adult":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,76,109,134,156,183,201,227,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":45},"100434863","adapting-for-latinx-populations-an-intervention-that-involves-discussing-and-sharing-patients-health-related-values-100434863",false,"NCT04942717","Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values","Communicating With Oncology Nurses About Values From the Outset (CONVO): An Innovative Primary Palliative Care Intervention in English and Espanol","Inclusion Criteria:\n\n* All participants will be adults (age ≥ 21) providing informed verbal consent. We seek a waiver of signed consent, which will allow use of virtual communication during the COVID-19 pandemic period.\n* Patients will be eligible as key informants in the translation\u002Ftranscreation process (Aim 1) if they are receiving medical oncology care for a solid tumor malignancy at RLC, SBH, or Jacobi and speak Spanish as their preferred language. In addition, English-speaking Latinx patients will be eligible to participate in interviews based on the back-translated (Spanish-to-English) version of the Guide\n\n  * We are focusing on patients with solid tumors rather than hematologic malignancies because 1) patients in the latter group may be receiving initial oncologic treatment in the hospital, whereas our study staff will be based at a distance from the hospital in the ambulatory clinics; 2) the trajectory, patient characteristics, and other aspects of hematologic malignancies tend to be different from solid tumor malignancies such that it would be more difficult to understand the overall impact of the intervention if patients with both types of malignancies w ere included.\n* Spanish-speaking family\u002Fother informal caregivers (collectively referred to as \"family\") who accompany participating patients to clinic will also be eligible to participate in interviews as part of the Aim 1 translation\u002Ftranscreation process. These will be individual interviews, conducted separately for patient and family participants.\n* Clinicians eligible for participation in the transcreation will be oncology physicians, nurses and other key clinical staff (e.g. social workers, advance practice providers, etc.) at RLC and other MSK sites who are Latinx and\u002For whose practice includes \\>20% Latinx patients.\n* Site leaders at SBH, Jacobi, and RLC with administrative responsibility for medical oncology will be eligible as key informants in transcreation of CONVO.\n* For the Aim 2 pilot trial, patients will be eligible if they are receiving systemic chemotherapy at SBH or Jacobi for a solid tumor; identify as Latinx; and speak English and\u002For Spanish. Family and\u002For informal caregivers who accompany the patient and speak English and\u002For Spanish will also be eligible (if the patient opts to include the family and\u002For informal caregiver in the CONVO discussion).\n* Nurses providing outpatient oncology care in chemotherapy areas at SBH or Jacobi will be eligible to participate in the pilot trial.\n\nExclusion Criteria:\n\n* Inability to understand consent procedure in either English or Spanish will be an exclusion. (The consenting professional will be bilingual \\[English\u002FSpanish\\] and able to explain and obtain consent in either language.)","ALL","21 Years",{"count":19,"type":20},234,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for each participant includes a discussion between the nurse and participant about the participant's health-related values.",[26,27,28],"Solid Tumor","Solid Tumor, Adult","Solid Tumor, Unspecified, Adult",[30,31,26,32,33],"Spanish speaking","Latinx","20-539","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2021-06-18",{"date":42,"type":20},"2027-06-18",{"name":33,"class":44},"OTHER",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100584924","ucsf-biobank-for-hereditary-cancers-and-tumor-associated-mutations-100584924","NCT06895681","UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations","UCSF Biobank for Studying Hereditary Cancers and Tumor-Associated Mutations","Inclusion Criteria:\n\nFor participants undergoing collection of tissue, ascites, and\u002For pleural effusions:\n\n1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.\n2. Individuals 18 years of age or older on the day of signing informed consent.\n3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and\u002For Individuals with a family history or personal history of cancer.\n4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):\n\n   1. Surgical resection\n   2. Biopsy (open, incisional, excisional, punch, core needle, and\u002For fine needle aspiration (FNA) are all permitted)\n   3. Paracentesis\n   4. Thoracentesis\n\nFor participants undergoing blood banking:\n\n1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.\n2. Individuals 18 years of age or older on the day of signing informed consent.\n3. Individuals with a family history or personal history of cancer.\n4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care.\n\nExclusion Criteria:\n\n1\\. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.","18 Years",{"count":55,"type":20},50000,"10 Years","OBSERVATIONAL","This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.",[26,27,60,28,61],"Somatic Mutation","Hereditary Cancer",[63,64],"Germline Mutations","Tumor-Associated Mutations","NOT_YET_RECRUITING","2026-04-28",{"date":68,"type":38},"2026-05-04",{"date":70,"type":20},"2026-08-31",{"date":72,"type":20},"2035-12-31",{"name":74,"class":44},"University of California, San Francisco",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100396514","phase-1-an-open-label-study-of-inv-1120-as-a-single-agent-and-in-combination-with-pembrolizumab-in-adult-patients-with-advanced-solid-tumors-100396514","NCT04443088","An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","A Phase 1a\u002F1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","KEYNOTE-E12","Inclusion Criteria:\n\n1. Written informed consent, according to local guidelines, signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses;\n2. Patient must be ≥18 years-of-age at the time of signature of the informed consent form (ICF);\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;\n4. Patients with histologically or cytologically confirmed advanced solid tumors which have progressed on or following standard therapy or for which no standard therapy exists;\n5. Patients with life expectancy ≥3 months;\n6. Patients with at least one measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), according to RECIST v1.1. Tumor lesions that have been irradiated ≥4 weeks before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions in the absence of measurable lesions that have not been irradiated;\n7. Patients whose laboratory data at screening meet the acceptable criteria for bone marrow, liver function and renal function.\n8. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test during screening. A woman is considered of childbearing potential (fertile) following menarche and until becoming postmenopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Postmenopausal women can be included;\n9. Male patients with female partners of childbearing potential and female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 3 months following last dose. Medically acceptable contraception includes:\n\n   * Hormonal methods (Needs to have been instituted at least 1 month prior to the first dose of study drug):\n   * Barrier methods:\n   * Abstinence, defined as refraining from sexual intercourse\n10. Male patients must also refrain from donating sperm from the first dose of study drug until 4 months after the last dose of study drug;\n11. Patients must be able to swallow and retain orally administered medication.\n\nExclusion Criteria:\n\n1. History (≤5 years) or current evidence of cancer that is histologically distinct from the cancer under study, except for cervical carcinoma in situ, superficial non-invasive bladder tumors, or curatively treated Stage I non-melanoma skin cancer. Patients with hepatocellular carcinoma will be excluded from Phase 1b dose escalation;\n2. Known serious allergy to investigational drug or excipients (microcrystalline cellulose);\n3. History of severe autoimmune disease (including significant ongoing immune-related adverse events of prior immune-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone \\>10 mg\u002Fday or equivalent);\n4. Known malignant central nervous system disease other than neurologically stable, treated brain metastases - defined as metastases having been treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of progression or hemorrhage and off any systemic corticosteroids for at least 4 weeks prior to signing the consent;\n5. History (within 4 weeks of starting treatment) or evidence of active infections (Grade ≥2);\n6. Seropositive status for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at any time before the start of treatment: Testing for seropositive status during screening will be at the discretion of the Investigator in patients without previously reported results;\n7. History or evidence of any severe and\u002For uncontrolled medical conditions or other conditions that, in the opinion of the Investigator and Sponsor, could affect the patient's participation in the study, such as any disorder or surgical procedure that could impact the absorption of study drug from the gastrointestinal tract.\n8. History (≤6 months before the start of treatment) or evidence of any of the following: acute myocardial infarction, unstable angina pectoris, coronary artery bypass graft, cerebrovascular accident, or transient ischemic attack;\n9. Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:\n\n   * Congenital long QT syndrome;\n   * Significant ventricular or supraventricular arrhythmias (patients with sinus arrhythmia or chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible);\n   * LVEF \\\u003C 50% by ECHO or MUGA;\n   * Other clinically significant heart disease such as known congestive heart failure New York Heart Association (NYHA) Class III-IV;\n10. Patients with QT interval ≥470 msec in females and ≥450 msec in males at screening using Fridericia's formula (determined as the mean of 3 QTcF values from the screening triplicate ECG obtained with adequate quality);\n11. Women who are pregnant or breastfeeding.\n12. WOCBP and sexually active fertile men with WOCBP partners who are unwilling or unable to use acceptable contraception method to avoid pregnancy for at least 1 month before the first dose of the study drug, during the study, and for 4 months after the last dose of study drug;\n13. Male patient who plans to father a child while enrolled in this study or within 4 months after the last dose of study drug;\n14. Not recovered from toxicity from prior anticancer therapy to baseline or Grade 1 (except toxicities which are not clinically significant such as alopecia, skin discoloration).\n15. History of an allogeneic bone marrow or solid organ transplant;\n16. Use of systemic anti-cancer agent (except luteinizing hormone-releasing hormone (LHRH) agonists, bisphosphonates and denosumab) or investigational drug ≤28 days or five half-lives whichever is shorter prior to the first dose of study treatment;\n17. Radiation therapy ≤28 days prior to the first dose of study treatment, or likely to require radiation therapy at any time until the 30 days after the last dose of study treatment, except for palliative radiation therapy limited to non-target bone lesions;\n18. Major surgery within 4 weeks before enrollment or surgery with ongoing post-operative complications);\n19. History of transfusion of platelets ≤2 weeks before the start of treatment;\n20. Patients who start erythropoietin or granulocyte-colony stimulating factor (G-CSF), pegfilgrastim, or filgrastim ≤3 weeks before screening;\n21. Patients taking medications known to have a significant risk of causing Torsades de Pointes. Patients who have discontinued any of these medications must have a wash-out period of at least 7 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug.\n22. History of use of H2 blockers (\\\u003C24 hours before the first dose of study treatment and during the study) and proton pump inhibitors (\\\u003C5 days before the first dose of study treatment and during the study).\n23. Patients with recent (within past 12 months) history, or are currently being treated for gastroesophageal ulcer.\n\n    The following additional exclusion criteria will apply to patients enrolling in Phase 1b:\n24. Have been discontinued treatment due to a Grade 3 or higher immune-related (irAE) from prior anti-PD-1 or anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) (only for dose expansion).\n25. Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of administration of investigational products.\n26. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.\n27. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n28. Has a history of (non-infectious) pneumonitis \u002F interstitial lung disease that required steroids or has current pneumonitis \u002F interstitial lung disease or radiation pneumonitis.",{"count":85,"type":20},78,[87],"PHASE1","Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.",[90,27,91,92,28,93],"Cancer","Cancer Metastatic","Solid Carcinoma","Tumor, Solid",[95,96,90,97],"Ionova","Ionova Bio","Oncology","2026-03-16",{"date":100,"type":38},"2026-03-18",{"date":102,"type":38},"2020-06-26",{"date":104,"type":20},"2026-12-31",{"name":106,"class":107},"Shenzhen Ionova Life Sciences Co., Ltd.","INDUSTRY",3,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100434084","gustave-roussy-cancer-profiling-100434084","NCT04932525","Gustave Roussy Cancer Profiling","STING","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Histology: solid malignant tumor or hematological malignancy.\n3. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)\n4. Voluntary signed and dated written informed consent prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol\n2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent\n3. Pregnant or breast-feeding women\n4. Minors (Age \\\u003C 18 years)",{"count":117,"type":20},20000,[23],"The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +\u002F- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.",[28],[122,123],"immunological profiling","targetable oncogenic aberration","2026-02-05",{"date":126,"type":38},"2026-02-06",{"date":128,"type":38},"2021-05-10",{"date":130,"type":20},"2033-05-10",{"name":132,"class":44},"Gustave Roussy, Cancer Campus, Grand Paris",4,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":75},"100411889","phase-1-phase-12a-study-of-mpb-1734-in-patients-with-advanced-solid-tumors-100411889","NCT04643418","Phase 1\u002F2a Study of MPB-1734 in Patients With Advanced Solid Tumors","Phase 1\u002F2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2","Inclusion Criteria:\n\n1. Signed informed consent in the local language prior to any study-mandated procedure.\n2. Male or female patients at least 18 years of age, at the time of informed consent.\n3. Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid tumor lesions (Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\]) that are unresectable, and standard therapy able to provide clinical benefit does not exist or is no longer effective.\n4. Eastern Cooperative Oncology Group Performance Status ≤2.\n5. Patients have recovered from the acute toxicity of previous therapies (peripheral sensory neuropathy recovered to ≤Grade 2) except alopecia, and:\n\n   * At least 4 weeks have elapsed since completing surgery, endocrine therapy, tyrosine kinase inhibitor therapy, immunotherapy, radiotherapy, chemotherapy, and\u002For\n   * At least 6 weeks have elapsed since completing chemotherapy with nitrosoureas, melphalan, and\u002For mitomycin C, and\u002For\n   * At least 6 weeks have elapsed since completing cranial radiotherapy.\n6. Life expectancy of greater than 12 weeks.\n7. Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. Peripheral sensory neuropathy \\>Grade 2 (CTCAE version 5.0) at baseline.\n2. Patients requiring immediate palliative treatment of any kind including surgery and\u002For radiotherapy.\n3. Serum bilirubin \\>1.5× ULN.\n4. AST and\u002For ALT \\>2.5× ULN if no liver involvement, OR AST and\u002For ALT \\>5× ULN with liver involvement.\n5. Serum creatinine \\>1.5× ULN, and\u002For a creatinine clearance of \\\u003C50 mL\u002Fmin calculated by Cockcroft Gault.\n6. QTc prolongation defined as a QTc with Framingham correction greater than or equal to 470 ms, or significant electrocardiogram (ECG) abnormalities.\n7. Known hypersensitivity to taxanes or any excipients of the drug formulation.\n8. Female patients who are pregnant, breast-feeding, or planning to become pregnant during the study.\n9. Untreated and\u002For uncontrolled central nervous system metastases.\n10. Patients with brain tumors, primary or metastatic.\n11. Patients taking concomitant medications anticipated to result in drug-drug interactions.",{"count":142,"type":20},81,[87,144],"PHASE2","This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1\u002F2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.",[28],"2025-10-30",{"date":149,"type":38},"2025-11-03",{"date":151,"type":38},"2022-03-08",{"date":153,"type":20},"2025-12",{"name":155,"class":107},"MegaPro Biomedical Co. Ltd.",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":133},"100403792","psychotherapy-intervention-for-latinos-with-adv-cancer-100403792","NCT04537936","Psychotherapy Intervention for Latinos With Adv Cancer","Adaptation and Pilot Feasibility of a Psychotherapy Intervention for Latinos With Advanced Cancer","Inclusion Criteria:\n\nPhase I: Quantitative\n\n* Diagnosed with stages III or IV solid tumor cancer \\*(as per self report for ICCAN patients)\n* Age 18 or older\n* As per self report, Latino\u002Fa or Hispanic ethnicity\n* As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual)\n\nPhase 2: Qualitative\n\n* Enrolled in the quantitative phase of study (as seen above)\n* Completes the quantitative phase questionnaire\n* Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3)\n* In the judgment of the investigator, willing and able to be interviewed in Spanish only\n* Agrees to be audio- recorded\n\nPhase 3: Provider Feedback\n\n* Professionals working in the mental health field;\n* Have a caseload of five or more Latino cancer patients per month\n* Able to communicate and read in Spanish\n* Agrees to be audio or video-recorded\n\nPhase 4: Patient Feedback\n\n* Diagnosed with stages III or IV solid tumor cancer \\*(as per self report for ICCAN patients)\n* Age 18 or older\n* As per self report, Latino\u002Fa or Hispanic ethnicity\n* In the judgment of the investigator, willing and able to be interviewed in Spanish only\n* Agrees to be audio-recorded\n\nPhase 5: Pilot RCT\n\n* Diagnosed with stages III or IV solid tumor cancer\n* Age 18 or older\n* Latino\u002Fa or Hispanic ethnicity\n* Fluent in oral Spanish (monolingual or bilingual)\n* Scores above the threshold for the Distress Thermometer (DT≥4)\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nPhase 1: Quantitative\n\n* In the judgment of the treating physician and\u002For the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection\n* In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)\n\nPhase 2: Qualitative\n\n* In the judgment of the treating physician and\u002For the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection\n* In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)\n\nPhase 4: Patient Feedback\n\n* Diagnosed with a major disabling medical or psychiatric condition\n* Unable to understand the consent procedure\n* Too ill to participate, all as reported by the patient and\u002For determined by the investigator's judgment.\n\nPhase 5: Pilot RCT\n\n* Diagnosed with a major disabling medical\n* Diagnosed with a major disabling psychiatric condition\n* Unable to understand the consent procedure\n* Too ill to participate, all as reported by the patient and\u002For determined by the investigator's judgment",true,{"count":165,"type":20},285,[23],"The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus on Latinos. We are interested in understanding what affects Latino patients' quality of life, and how to improve it",[26,27,28],[170,171,172,173,174,33,175],"Stage III solid tumor cancer","Stage IV solid tumor cancer","Stage III cancer","Stage IV cancer","Spanish","15-076","2025-10-08",{"date":178,"type":38},"2025-10-09",{"date":180,"type":38},"2019-01-01",{"date":70,"type":20},{"name":33,"class":44},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":161,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":163,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":167,"conditions":192,"keywords":193,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":133},"100363699","psychotherapy-intervention-for-latinos-with-advanced-cancer-100363699","NCT04015609","Psychotherapy Intervention for Latinos With Advanced Cancer","Inclusion Criteria:\n\nPhase I: Quantitative\n\n* Diagnosed with stages III or IV solid tumor cancer \\*(as per self report for ICCAN patients)\n* Age 18 or older\n* As per self report, Latino\u002Fa or Hispanic ethnicity\n* As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual)\n\nPhase 2: Qualitative\n\n* Enrolled in the quantitative phase of study (as seen above)\n* Completes the quantitative phase questionnaire package\n* Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3)\n* In the judgment of the investigator, willing and able to be interviewed in Spanish only\n* Agrees to be audio- recorded\n\nPhase 3: Provider Feedback\n\n* Professionals working in the mental health field;\n* Have a caseload of five or more Latino cancer patients per month\n* Able to communicate and read in Spanish\n* Agrees to be audio or video-recorded\n\nPhase 4: Patient Feedback\n\n* Diagnosed with stages III or IV solid tumor cancer \\*(as per self report for ICCAN patients)\n* Age 18 or older\n* As per self report, Latino\u002Fa or Hispanic ethnicity\n* In the judgment of the investigator, willing and able to be interviewed in Spanish only\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nPhase 1: Quantitative\n\n* In the judgment of the treating physician and\u002For the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection\n* In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)\n\nPhase 2: Qualitative\n\n* In the judgment of the treating physician and\u002For the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For data collection\n* In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)\n\nPhase 4: Patient Feedback\n\n* Diagnosed with a major disabling medical or psychiatric condition\n* Unable to understand the consent procedure\n* Too ill to participate, all as reported by the patient and\u002For determined by the investigator's judgment.",{"count":190,"type":20},190,[23],[26,27,28],[170,171,172,173,174,33,175],"2025-09-30",{"date":196,"type":38},"2025-10-02",{"date":198,"type":38},"2015-04-20",{"date":70,"type":20},{"name":33,"class":44},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":108},"100586127","phase-1-ad1208-in-subjects-with-any-progressive-locally-advanced-or-metastatic-solid-tumors-100586127","NCT06911333","AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","A Phase I\u002FIIa Trial of AD1208, a Cell Cycle Inhibitor\u002FMASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors","AD1208","Inclusion Criteria:\n\n* Male or female subjects ≥19 years of age\n* Willing to consent to participate in study and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures\n* Histologically and\u002For cytologically confirmed any progressive, locally advanced (unresectable), or metastatic solid tumors that have relapsed or are refractory following the last line of treatment and for which prior standard therapy has been ineffective, standard therapy does not exist or is not considered appropriate.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Life expectancy of at least 12 weeks\n* Subjects with adequate hematologic, hepatic, and renal functions confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP.\n* Female subject who is surgically sterile, is postmenopausal, or agrees to use a highly effective method of birth control (2 methods strongly recommended) during the study and for 6 months following the last dose of IP.\n* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time the partner is breastfeeding throughout the study period and for 6 months after the final administration of IP.\n\nExclusion Criteria:\n\n* Untreated active brain metastases.\n* has leptomeningeal disease.\n* unrecovered \\> Grade 1 from the adverse event of prior therapy except for alopecia.\n* has an active autoimmune disease requiring systemic treatment within the past 2 years.\n* Active interstitial lung disease (ILD) or pneumonitis or a history of ILD.\n* Subject has received the following treatment;\n\n  * prior anticancer monoclonal antibody treatment or investigational therapy\n  * prior any chemotherapy\n  * prior radiotherapy\n  * Major surgery\n* Clinically significant (i.e., active) cardiovascular disease\n* known positive of human immunodeficiency virus (HIV) infection.\n* Active hepatitis B or C subjects.\n* known allergic reaction for active ingredients or inactive ingredients such as excipients of Investigational product.\n* Live vaccine administered against infectious disease.\n* Gastrointestinal (GI) track disease causing the inability to take oral medication, malabsorption syndrome or uncontrolled inflammatory GI disease.\n* having psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* women with a positive pregnancy test at screening test.\n* women who are breast feeding.\n* subject has any condition because of which, in the opinion of the investigator, the participation would not be in the best interest of the subject.","19 Years",{"count":211,"type":20},36,[87,144],"The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are:\n\n* Which dosage of AD1208 is safe and tolerable for participants?\n* What medical problems do participants have when taking AD1208?\n\nParticipants will:\n\n* Take drug AD1208 every day up to 1 cycle at the least.\n* Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards.\n* Keep a diary of any adverse events and administrated drug",[27,93,26,28,215,216,217],"Solid Tumor Cancer","Solid Tumors Refractory to Standard Therapy","Solid Tumor in Advanced Stage","2025-03-28",{"date":220,"type":38},"2025-04-04",{"date":222,"type":38},"2025-03-11",{"date":224,"type":20},"2030-02-20",{"name":226,"class":107},"Avelos Therapeutics Inc.",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":245,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100583992","phase-1-a-phase-i-study-of-lxp1788-injection-with-advanced-solid-tumors-100583992","NCT06883539","A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.","A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.","Inclusion Criteria:\n\n1. Written (signed) Informed Consent.\n2. Male or female ≥ 18 years old.\n3. Life expectancy \\> 8 weeks.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. A histologically or cytologically confirmed, advanced solid tumor that is refractory to currently available therapies or for which no effective treatment is available.\n6. Measurable disease per RECIST 1.1.\n7. Willing to have a tumor biopsy or having tissue sample from a previous biopsy available in the tissue bank for analysis that had been collected in the past 3 years.\n\nExclusion Criteria:\n\n1. Significant concurrent medical diseases, such as congestive heart failure, unstable angina, acute or recent myocardial infarction (\\\u003C 6 months before enrollment), COPD with frequent exacerbations, uncontrolled hypertension (systemic blood pressure \\>= 160 mmHg and\u002For diastolic blood pressure \\>= 100 mmHg with or without anti-hypertensive medication), recent CVA (\\\u003C 6 months before enrollment), or active infection which requires treatment withintravenous antibiotics.\n2. Patients with symptomatic CNS metastases who are neurologically unstable, receiving radiotherapy for the CNS lesion, or requiring increasing dose of steroids to control their CNS disease.\n\n   Asymptomatic patients with metastatic brain disease who have been on a stable dose of steroids for less than 14 days prior to screening.\n3. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n   Bone marrow:\n   * Absolute neutrophil count (ANC) \\\u003C 1.5 x 10\\^9\u002FL\n   * Platelet count \\\u003C 100 x 10\\^9\u002FL\n   * Hemoglobin \\\u003C 9 g\u002FdL\n   * Having had a blood transfusion within 2 weeks of screening date is also not allowed.\n\n   Hepatic:\n   * Total bilirubin \\> 1.5 x ULN\n   * AST and ALT \\> 3 x ULN if no liver metastases\n   * AST and ALT \\> 5 x ULN in the presence of liver metastases\n\n   Renal:\n\n   ⚫ Estimated creatinine clearance (CrCL) \\\u003C 60 mL\u002Fmin per the Cockcroft and Gault formula\n4. Known history of human immunodeficiency virus (HIV)-1 or -2 infection.\n5. Psychiatric disorders that would compromise the patient's compliance or ability to give consent.\n6. Major surgical intervention within 4 weeks of the first dose of LXP1788 Injection or with ongoing postoperative complications.\n7. Toxicities from any prior therapy, surgery, or radiotherapy that did not resolve to grade 0 or 1 as per the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, with the exception of alopecia, skin hyperpigmentation or hypopigmentation.\n8. Underlying medical conditions that, in the investigator's opinion, will make the administration of LXP1788 Injection hazardous or obscure the interpretation of toxicities or adverse events.\n9. Exposure to any other investigational or commercial anti-cancer agents or curative therapies within 28 days or 5 half-lives (whichever is shorter), before the first dose of LXP1788 Injection. Exposure to radiation therapy for non-curative purposes or pain control may be permitted under the judgement of the investigator.\n10. Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures, restrictions, or requirements.\n11. Pregnancy or breast feeding.\n12. Women or men of childbearing potential not willing to use effective means of contraception.\n13. Positive test for hepatitis B (HBsAg) or hepatitis C (positive HCV antibody with detectable HCV RNA).\n14. History of allergic reactions to any component of LXP1788 Injection.",{"count":235,"type":20},24,[87],"A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor.\n\nPatients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected.\n\nThe main questions it aims to answer are:\n\n1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection\n2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection",[239,240,215,28,241,216,242,243,244],"Solid Tumor Malignancies, Cancer","Solid Cancers","Solid Tumour","HCC - Hepatocellular Carcinoma","RCC, Renal Cell Cancer","Pancreas Cancer",[246,247,248,249,250,251,252,253,254,255],"Phase 1","LXP1788","LAUNXP","DBPR114-101","solid tumor","cancer","Hepatocellular carcinoma","Pancrease Cancer","Renal Cell Carcinoma","Tyrosine kinase inhibitor","2025-03-12",{"date":258,"type":38},"2025-03-19",{"date":260,"type":38},"2024-12-31",{"date":262,"type":20},"2028-06-30",{"name":264,"class":107},"LaunXP Biomedical Co., Ltd.",2,{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":273,"targetDuration":275,"studyType":57,"phases":4,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":75},"100492706","proseq-cancer-genomic-profiling-in-patients-with-incurable-cancer-in-search-for-targeted-treatment-100492706","NCT05695638","Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","Proseq Cancer: A Prospective Study of Comprehensive Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","Inclusion Criteria:\n\n* Incurable, progressing and\u002For life-threatening cancer\n* Expected residual survival of at least 3 months\n* No efficient remaining standard treatment options\n* Patient recruited from the Region of Northern Jutland, Denmark\n\nExclusion Criteria:\n\n* WHO Performance Status \\>2\n* Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment",{"count":274,"type":20},3000,"5 Years","Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region.\n\nTreatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.",[28,278],"Haematological Malignancy",[280,281,282,283],"Precision medicine","Personalized medicine","Genomic profiling","Tissue agnostic","2024-01-30",{"date":286,"type":38},"2024-01-31",{"date":288,"type":38},"2020-07-01",{"date":290,"type":20},"2035-05-31",{"name":292,"class":44},"Morten Ladekarl"]